Day: May 12, 2022

Posted on

SOLVE FSHD Anuncia Nomeação da Diretora Executiva Dra. Eva Chin e Estrutura de Financiamento Filantrópico de Empreendimento

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) — Após o recente aclamado lançamento da SOLVE FSHD, a organização tem o prazer de anunciar formalmente a nomeação da Dra. Eva Chin como Diretora Executiva. O fundador da SOLVE FSHD, Chip Wilson, se comprometeu pessoalmente com US $ 100 milhões para encontrar a cura da distrofia muscular facioscapulo-umeral (FSHD), uma doença rara com a qual foi diagnosticado aos 32 anos de idade. Como primeira Diretora Executiva inaugural da SOLVE FSHD, a Dra. Chin será responsável por alinhar os objetivos da organização com a experiência dos pesquisadores, cientistas e empresas para promover e financiar a descoberta e desenvolvimento de novas terapias para FSHD.

“A experiência e a especialização da Dra. Chin em doenças neuromusculares raras agregam imenso valor à nossa organização. Estamos entusiasmados em receber sua experiência e orientação para alcançar o objetivo da organização de encontrar uma cura para a FSHD até dezembro de 2027”, disse Chip Wilson, fundador da SOLVE FSHD. Ele acrescentou: “Em apenas algumas semanas após o lançamento da organização, a SOLVE FSHD recebeu uma tremenda resposta ao pedido de subsídios qualificados e novas tecnologias terapêuticas, que serão avaliadas sob a liderança da Dra. Chin. Além disso, ela trabalhou incansavelmente na criação de fortes alianças da indústria com a SOLVE FSHD, avaliou de perto os projetos emocionantes para financiar e facilitou oportunidades de financiamento colaborativo em todos os setores acadêmicos e da indústria em pesquisa FSHD e desenvolvimento de drogas.”

A Dra. Chin obteve seu Ph.D. em Fisiologia na University of Waterloo, no Canadá, e completou o treinamento de pós-doutorado na University of Sydney, Austrália e U.T. Southwestern Medical Center em Dallas, com foco no cálcio intracelular na fadiga muscular e regulação transcricional da expressão gênica na determinação do tipo de fibra muscular e plasticidade muscular.

“Tenho a honra de fazer parte da equipe da Solve FSHD, apoiando Chip e a Família Wilson na nossa missão de melhorar a qualidade de vida das pessoas afetadas por doenças neuromusculares raras, financiando projetos de pesquisa qualificados e pesquisas pré-clínicas e clínicas que acelerarão a busca de uma cura para a FSHD”, disse a Dra. Eva Chin, Diretora Executiva da Solve FSHD.

A carreira da Dra. Chin abrangeu as indústrias acadêmica e farmacêutica, com cargos anteriores na Pfizer, University of Maryland, MyoTherapeutics, Cytokinetics e NMD Pharma. Na Pfizer, a Dra. Eva mudou sua carreira de pesquisa acadêmica com foco em mecanismos celulares e moleculares da função muscular para descobrir e desenvolver terapias direcionadas aos músculos. Nos últimos cinco anos, ela liderou o desenvolvimento não clínico de inúmeros candidatos a medicamentos em ensaios clínicos para ELA, SMA, miastenia gravis e cardiomiopatia hipertrófica.

Sob a orientação do Dr. Chin, o modelo de empreendimento de financiamento filantrópico da Solve FSHD utilizará estrategicamente a doação de Wilson para apoiar as doações iniciais, investimentos em empresas em estágio inicial focadas em FSHD e para incentivar as empresas farmacêuticas no espaço de doenças neuromusculares a aumentar seu foco em FSHD. O modelo de filantropia do empreendimento permitirá que a organização seja financeiramente autossustentável por meio do retorno dos investimentos. Os investimentos em oportunidades de pesquisa viáveis, embora de alto risco, podem gerar um fluxo contínuo de reinvestimento na organização para apoiar ainda mais as iniciativas de financiamento de doações.

“Para aproveitar os recentes avanços na terapia genética, a SOLVE FSHD criou uma plataforma de financiamento criativa para facilitar o desenvolvimento de tratamentos que retardam, param ou até revertem rapidamente a fraqueza da FSHD”, disse o Dr. John Day, MD, Ph.D., Diretor do programa de Medicina Neuromuscular da Stanford University. “Uma pessoa com a experiência e a capacidade da Dra. Eva Chin participando da SOLVE FSHD é fundamental para estabelecer o programa cientificamente rigoroso necessário para definir e validar tratamentos seguros e eficazes o mais rápido possível”, disse Dr. John Day, MD, Ph.D., Neuromuscular Medicine, Stanford Neuroscience Health Center.

Sobre a Solve FSHD
A Solve FSHD está financiando atividades inovadoras de pesquisa e desenvolvimento de biotecnologia e biofármacos que aceleram novos tratamentos para distrofia muscular facioscapulo-umeral (FSHD). O programa é totalmente financiado e criado pelo empresário e filantropo canadense Chip Wilson. O fundador da Lululemon Athletica inc., empresa de vestuário atlético inspirado na yoga tem FSHD há três décadas. Ele investiu US$ 100 milhões do seu próprio dinheiro para criar a SOLVE FSHD para financiar projetos que se encaixam na missão da organização: acelerar a pesquisa de novas terapias e encontrar uma cura para a doença até 2027.

Anúncios futuros de financiamento de subsídios serão publicados no site da Solve FSHD https://solvefshd.com/ Empresas iniciantes, devem entrar em contato com a SOLVE FSHD em [email protected].

Quem tiver FSHD e quiser obter mais informações sobre ensaios clínicos ou ser incluído no registro de FSHD, deve consultar o site da SOLVE FSHD em https://solvefshd.com/

Para perguntas da mídia ou para solicitar uma entrevista da mídia, contate:
Kamran Shaikh, Diretor de Contas
PR Associates
[email protected]
778-846-5406

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/0e87aacb-92f4-4723-9e7e-e24021cff5f7

Posted on

SOLVE FSHD annonce la nomination de la Dre Eva Chin en tant que directrice exécutive et la structure de financement par « venture philanthropie »

VANCOUVER, Colombie-Britannique, 11 mai 2022 (GLOBE NEWSWIRE) — Suite au récent lancement acclamé de SOLVE FSHD, l’organisation a le plaisir d’annoncer officiellement la nomination de la Dre Eva Chin au poste de directrice exécutive. Le fondateur de SOLVE FSHD, Chip Wilson, a personnellement engagé 100 millions USD pour trouver un traitement contre la dystrophie musculaire facio-scapulo-humérale (FSHD), une maladie rare qui lui a été diagnostiquée à l’âge de 32 ans. En tant que première directrice exécutrice de SOLVE FSHD, la Dre Chin sera chargée d’aligner les objectifs de l’organisation avec l’expertise des chercheurs, des scientifiques et des entreprises afin de promouvoir et de financer la découverte et le développement de nouvelles thérapies pour lutter contre la FSHD.

« L’expérience et la spécialisation de la Dre Chin dans les maladies neuromusculaires rares ajoutent une immense valeur à notre organisation. Nous sommes ravis de profiter de son expertise et de ses conseils pour atteindre l’objectif de l’organisation consistant à trouver un remède pour la FSHD d’ici décembre 2027 », a déclaré Chip Wilson, fondateur de SOLVE FSHD. « Seulement quelques semaines après le lancement de l’organisation, l’appel de SOLVE FSHD en faveur de demandes de subvention qualifiées et de nouvelles technologies thérapeutiques a reçu une réponse exceptionnelle, et elles seront examinées sous la direction de la Dre Chin », a-t-il ajouté. « En outre, elle a travaillé sans relâche pour construire de solides alliances industrielles pour SOLVE FSHD, elle a évalué minutieusement les projets passionnants visant à financer et à faciliter les opportunités de financement collaboratif dans les secteurs académique et industriel de la recherche et le développement de médicaments contre la FSHD. »

La Dre Chin a obtenu son doctorat en physiologie à l’université de Waterloo au Canada et a suivi une formation post-doctorale à l’université de Sydney, en Australie et à l’U.T. Southwestern Medical Center, à Dallas, se concentrant sur le rôle du calcium intracellulaire dans la fatigue musculaire et la régulation transcriptionnelle de l’expression du gène dans la détermination du type de fibre musculaire et la plasticité musculaire.

« C’est un honneur pour moi de rejoindre l’équipe de SOLVE FSHD, afin de soutenir Chip et la famille Wilson dans notre mission visant à améliorer la qualité de vie des personnes touchées par des maladies neuromusculaires rares en finançant des projets de recherche qualifiés et des recherches précliniques et cliniques qui accéléreront la découverte d’un traitement pour la FSHD », a déclaré la Dre Eva Chin, directrice exécutive de SOLVE FSHD.

Au cours de sa carrière, la Dre Chin a travaillé dans les secteurs académique et pharmaceutique, avec des postes précédents chez Pfizer, à l’université du Maryland, ainsi que chez MyoTherapeutics, Cytokinetics et NMD Pharma. Chez Pfizer, Eva est passée de la recherche universitaire axée sur les mécanismes cellulaires et moléculaires de la fonction musculaire à la découverte et au développement de thérapies ciblant les muscles. Au cours des cinq dernières années, elle a dirigé le développement non clinique de nombreux médicaments candidats dans des essais cliniques portant sur la SLA, la SMA, la myasthénie grave et la cardiomyopathie hypertrophique.

Sous la direction de la Dre Chin, le modèle de financement par « venture philanthropie »  de SOLVE FSHD utilisera stratégiquement l’engagement financier de Wilson pour soutenir les subventions initiales, les investissements dans des jeunes entreprises axées sur la FSHD et inciter les compagnies pharmaceutiques dans le domaine des maladies neuromusculaires à se concentrer davantage sur la FSHD. Le modèle de « venture philanthropie » permettra à l’organisation d’être financièrement autonome grâce au retour sur investissements. Les investissements dans des opportunités de recherche viables, malgré un risque élevé, peuvent générer un flux continu de réinvestissement dans l’organisation pour soutenir davantage les initiatives de financement par subventions.

« Pour profiter des récentes avancées dans le domaine des thérapies génétiques, SOLVE FSHD a construit une plateforme de financement créative afin de faciliter le développement de traitements qui ralentissent, arrêtent ou inversent rapidement la faiblesse de la FSHD », a déclaré le Dr John Day, MD, Ph.D., directeur du programme de médecine neuromusculaire de l’université de Stanford. « Le fait que quelqu’un possédant l’expérience et les compétences de la Dre Eva Chin rejoigne SOLVE FSHD est essentiel pour établir le programme scientifiquement rigoureux nécessaire pour définir et valider des traitements sûrs et efficaces le plus rapidement possible », a déclaré le Dr John Day, MD, Ph.D., médecine neuromusculaire, Stanford Neuroscience Health Center.

À propos de SOLVE FSHD
SOLVE FSHD finance des activités de recherche et de développement biotechnologiques et biopharmaceutiques innovantes qui accélèrent les nouveaux traitements contre la dystrophie musculaire facio-scapulo-humérale (FSHD). L’initiative est entièrement financée et créée par l’entrepreneur et philanthrope canadien Chip Wilson. Le fondateur de la société de vêtements d’athlétisme inspirés par le yoga Lululemon Athletica Inc. souffre de FSHD depuis trois décennies. Il a consacré 100 millions de dollars de son propre argent pour créer SOLVE FSHD et lancer un financement dans des projets qui correspondent à la mission de l’organisation : accélérer la recherche sur de nouvelles thérapies et trouver un remède contre la maladie d’ici 2027.

Les prochaines annonces de financement de subventions seront publiées sur le site Web de SOLVE FSHD – https://solvefshd.com/. Pour les entreprises en phase de démarrage, contacter SOLVE FSHD à l’adresse [email protected].

Si vous êtes atteint(e) de FSHD et souhaitez en savoir plus sur les essais cliniques ou être inclus(e) dans le registre FSHD, veuillez consulter le site Web de SOLVE FSHD – https://solvefshd.com/

Pour toute demande d’ordre médiatique ou d’entretien à des fins médiatiques, veuillez contacter :
Kamran Shaikh, directeur de compte
PR Associates
[email protected]
778-846-5406

Une photo accompagnant cette annonce est disponible à l’adresse https://www.globenewswire.com/NewsRoom/AttachmentNg/0e87aacb-92f4-4723-9e7e-e24021cff5f7

Posted on

Synchronoss Finalizes Agreement with iQmetrix to Divest Digital Experience Platform and Activation Solutions

BRIDGEWATER, N.J., May 11, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced the successful completion of the sale of its Digital Experience Platform (“DXP”) and Activation Solutions (“Activation”) to iQmetrix, a leading provider of telecom retail management software. The divestiture was formally announced on March 8, 2022.

“The sale of DXP and Activation is part of our strategic plan to create a leaner business model that focuses on our core growth areas for the future,” said Jeff Miller, President, and Chief Executive Officer of Synchronoss. “Closing this deal is favorable for Synchronoss’s long-term product focus areas. It provides us with operating flexibility to improve our capital structure and to accelerate the development of new product offerings in our key areas such as our cloud portfolio.”

“As a trusted provider of intelligent retail management software, iQmetrix is the natural acquirer of choice for the Digital Experience Platform and Activation Solutions,” said Ryan Volberg, President and Chief Executive Officer of iQmetrix. “We’re very excited as this supports our plans to be the number one enabler of personal connected devices globally. In such a relentlessly changing industry, this is the next big step of many that we’re excited to take to help us create great experiences in the telecom space.”

The DXP and Activation offerings enable telecom operators and retailers around the globe to create, orchestrate and manage digital experiences across all channels. Following the sale, the Synchronoss digital business portfolio includes its Financial Analytics and spatialSUITE products as well as the iNow Platform.

About Synchronoss
Synchronoss Technologies (Nasdaq: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services, and content they love. That’s why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at www.synchronoss.com.

Media Relations Contact:
Domenick Cilea
Springboard
[email protected]

Investor Relations Contact:
Matt Glover / Tom Colton
Gateway Group, Inc.
[email protected]

Posted on

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Riskified Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RSKD

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Riskified Ltd. (NYSE: RSKD) pursuant and/or traceable to the Registration Statement issued in connection with the Company’s initial public offering conducted on or about July 28, 2021 (the “IPO” or “Offering”), of the important July 1, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Riskified securities pursuant and/or traceable to the IPO you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Riskified class action, go to https://rosenlegal.com/submit-form/?case_id=5896 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 1, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO Registration Statement was negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Specifically, the IPO Registration Statement made inaccurate statements of material fact because they failed to disclose the following adverse facts that existed at the time of the IPO: (1) as Riskified expanded its user base, the quality of Riskified’s machine learning platform had deteriorated (rather than improved as represented in the Registration Statement), because of, among other things, inaccuracies in the algorithms associated with onboarding new merchants and entering new geographies and industries; (2) Riskified had expanded its customer base into industries with relatively high rates of fraud – including partnerships with cryptocurrency and remittance business – in which Riskified had limited experience and that this expansion has negatively impacted the effectiveness of Riskified’s machine learning platform; (3) as a result, Riskified was suffering from materially higher chargebacks and cost of revenue and depressed gross profits and gross profit margins during its third fiscal quarter of 2021; and (4) thus, the Registration Statement’s representations regarding Riskified’s historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of Riskified prior to and at the time of the IPO, and were materially false and misleading, and lacked a factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Riskified class action, go to https://rosenlegal.com/submit-form/?case_id=5896 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

Posted on

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – LICY, PDAC

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. (NYSE: LICY, PDAC) between February 16, 2021 and March 23, 2022, inclusive (the “Class Period”), of the important June 20, 2022 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Li-Cycle securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Li-Cycle class action, go to https://rosenlegal.com/submit-form/?case_id=4885 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 20, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Li-Cycle’s largest customer, Traxys North America LLC, is not actually a customer, but merely a broker providing working capital financial to the Company while Traxys tries to sell Li-Cycle’s product to end customers; (2) the Company engaged in highly questionable related party transactions; (3) the Company’s mark-to-model accounting is vulnerable to abuse and gave a false impression of growth; (4) a significant portion of the Company’s reported revenues were derived from simply marking up receivables on products that had not been sold; (5) the Company’s gross margins have likely been negative since inception; (6) the Company will require an additional $1 billion of funding to support its planned growth (which is a figure greater than the Company raised via the merger); and (7) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Li-Cycle class action, go to https://rosenlegal.com/submit-form/?case_id=4885 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

Posted on

ROSEN, A LEADING LAW FIRM, Encourages Natera, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTRA

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Natera, Inc. (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 27, 2022.

SO WHAT: If you purchased Natera securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Natera class action, go to https://rosenlegal.com/submit-form/?case_id=3115 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 27, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Natera class action, go to https://rosenlegal.com/submit-form/?case_id=3115 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

Posted on

Reuters s’associe à la plateforme d’automatisation Sophi.io de The Globe and Mail

TORONTO, 11 mai 2022 (GLOBE NEWSWIRE) — Sophi.io, une plateforme d’automatisation, d’optimisation et de prédiction basée sur l’IA développée par The Globe and Mail, travaille désormais avec Reuters, la division actualités et médias de Thomson Reuters, alors qu’elle continue d’investir dans les dernières solutions d’IA pour sa salle de rédaction. Sophi aide à automatiser la curation de contenu sur certaines sections de Reuters.com, qui a été relancée en avril 2021.

Sophi Site Automation est un système d’IA qui gère de manière autonome le contenu numérique pour trouver et promouvoir le contenu le plus attrayant d’une organisation. Sophi examine tout le contenu tel qu’il est publié, et tout le trafic, pour trouver les joyaux cachés que les clients d’une organisation apprécient le plus.

Afin d’automatiser la curation du contenu, l’algorithme de Sophi a appris auprès des rédacteurs de Reuters. La salle de rédaction a été en mesure de travailler avec certaines des dernières solutions d’IA, ce qui a permis aux rédacteurs de se concentrer sur la recherche de la prochaine histoire et de créer le journalisme qui fait de Reuters une marque si réputée.

Josh London, responsable de Reuters Professional et directeur du marketing de Reuters, a déclaré : « La plateforme d’IA de pointe de Sophi est l’une des prochaines étapes de l’évolution de nos propriétés numériques. Sophi nous aidera à poursuivre notre mission consistant à apporter des technologies et des outils basés sur l’IA à davantage d’employés, tout en aidant à apporter à nos lecteurs les histoires qu’ils veulent et ont besoin de connaître. »

Michael Young, directeur de la technologie chez Reuters, a déclaré : « Notre partenariat avec Sophi.io est un autre exemple de la manière dont une salle de rédaction comme la nôtre peut déployer avec succès certaines des dernières solutions d’IA pour une découverte de contenu efficace.Notre équipe a travaillé en étroite collaboration avec celle de Sophi pour garantir que notre score Sophi reflète nos objectifs commerciaux et nous sommes ravis de l’automatisation du site qui en résulte. »

Mike O’Neill, cofondateur et PDG de Sophi.io, a ajouté : « Nous sommes ravis d’accueillir Reuters en tant que client. Ils font confiance à Sophi et nous sommes ravis d’automatiser la curation sur l’ensemble de leurs pages d’articles afin de commencer et d’étendre la relation pour inclure davantage de solutions à l’avenir. »

« C’est formidable de travailler avec Reuters dans ce contexte », a déclaré Phillip Crawley, éditeur et PDG de The Globe and Mail. « Ils ont une mission forte et Sophi.io les aide à continuer de démontrer comment l’intégrité éditoriale peut être soutenue par l’IA. »

À propos de Reuters
Reuters est le premier fournisseur mondial d’actualités, d’informations et d’analyses de confiance, atteignant des milliards de personnes dans le monde chaque jour. Fondée en 1851, elle réunit un journalisme de classe mondiale, une expertise industrielle et une technologie de pointe avec une vitesse, une fiabilité et une précision inégalées pour permettre aux gens de prendre de meilleures décisions. Reuters s’engage à respecter les principes de confiance d’indépendance, d’intégrité et d’absence de parti pris, et est la source essentielle d’actualités commerciales, financières et mondiales fournies aux professionnels de la finance exclusivement via les services Refinitiv, ainsi qu’aux organisations médiatiques, aux événements du secteur et directement aux consommateurs du monde entier.

À propos de Sophi.io
Sophi.io (https://www.sophi.io) a été développée par The Globe and Mail pour aider les éditeurs de contenu à prendre des décisions stratégiques et tactiques importantes. Il s’agit d’une suite de solutions d’automatisation, d’optimisation et de prévision basées sur l’IA et l’AM qui comprend Sophi Site Automation, Sophi for Paywall et Sophi for First Party Data. Sophi permet également la mise en page automatisée en un clic de l’édition imprimée sans modèle. Sophi vise à améliorer les mesures qui comptent le plus pour votre entreprise, telles que la rétention et l’acquisition d’abonnés, l’engagement, la récence, la fréquence et le volume.

Nous contacter
Kayley Rogers
Responsable des communications
Reuters
Kayley.rogers@thomsonreuters.com

Jamie Rubenovitch
Resonsable marketing, Sophi.io
The Globe and Mail        
[email protected]
416-585-3355
Posted on

Reuters faz parceria com a Plataforma de Automação Sophi.io da The Globe and Mail

TORONTO, May 11, 2022 (GLOBE NEWSWIRE) — A Sophi.io, uma plataforma de automação, otimização e previsão alimentada por IA desenvolvida pela The Globe and Mail, está trabalhando com a Reuters – divisão de notícias e mídia da Thomson Reuters – enquanto continua investindo nas mais recentes soluções de IA para sua redação. A Sophi está ajudando a automatizar a curadoria de conteúdo em seções selecionadas na Reuters.com, que foi relançada em abril de 2021.

Sophi Site Automation organiza autonomamente conteúdo digital para encontrar e promover os artigos de conteúdos cativantes. Sophi analisa todo o conteúdo quando publicado e todo o tráfego, para encontrar o que os clientes de uma organização mais valorizam.

Para automatizar a curadoria de conteúdo, o algoritmo da Sophi está aprendendo com os editores da Reuters. A redação conseguiu trabalhar com algumas das mais recentes soluções de IA, resultando em mais tempo para editores se concentrarem em encontrar a próxima história e criar o jornalismo que torna a Reuters uma marca tão confiável.

Josh London, Diretor Profissional e Diretor de Marketing da Reuters, disse: “A plataforma de IA de ponta da Sophi é um dos próximos passos na evolução das nossas propriedades digitais. A Sophi nos ajudará a promover a nossa missão de levar a tecnologia e as ferramentas com base em IA para a nossa equipe de trabalho, ao mesmo tempo em que ajudará a levar aos nossos leitores as histórias que eles querem e precisam saber.”

Michael Young, Diretor de Tecnologia da Reuters, disse: “Nossa parceria com a Sophi.io é outro exemplo de como uma redação como a nossa pode implantar com sucesso algumas das mais recentes soluções de IA para a descoberta eficaz de conteúdo. A nossa equipe trabalhou em estreita colaboração com a equipe da Sophi para garantir que a pontuação da Sophi refletisse nossas metas de negócios. Estamos satisfeitos com a automação resultante do site.”

Mike O’Neill, cofundador e CEO da Sophi.io, acrescentou: “É um grande prazer ter a Reuters como cliente. Eles depositaram a confiança na Sophi e estamos empolgados em automatizar a curadoria em todas as páginas de artigos para iniciar e expandir o relacionamento para incluir mais soluções no futuro.”

“É muito bom trabalhar com a Reuters assim”, disse Phillip Crawley, Editor e CEO da The Globe and Mail. “Eles têm uma missão forte e a Sophi.io está viabilizando que eles continuem a demonstrar como a integridade editorial pode ser apoiada pela IA.”

Sobre a Reuters
A Reuters é a principal provedora mundial de notícias, insights e análises confiáveis, atingindo bilhões de pessoas diariamente em todo o mundo. Fundada em 1851, ela reúne jornalismo de classe mundial, experiência da indústria e tecnologia de ponta com velocidade, confiabilidade e precisão incomparáveis para permitir que as pessoas tomem melhores decisões. A Reuters está comprometida com os Princípios de Confiança de independência, integridade e liberdade de preconceitos, e é a fonte essencial de notícias de negócios, financeiras e mundiais entregues a profissionais financeiros exclusivamente através dos serviços Refinitiv, e às organizações de mídia do mundo, eventos da indústria e diretamente aos consumidores.

Sobre a Sophi.io
A Sophi.io (https://www.sophi.io) foi desenvolvida pela The Globe and Mail para ajudar os editores de conteúdo a tomar decisões estratégicas e táticas importantes. A empresa oferece um conjunto de soluções de automação, otimização e previsão com base em IA e ML, incluindo Sophi Site Automation, Sophi for Paywalls e Sophi for First Party Data. A Sophi também capacita o laydown automatizado de um clique da publicação impressa sem modelos. A Sophi foi projetada para aprimorar as métricas que mais importam para sua empresa, como retenção e aquisição de assinantes, engajamento, recentidade, frequência e volume.

Contato EUA
Kayley Rogers
Gerente de Comunicações
Reuters
Kayley.rogers@thomsonreuters.com

Jamie Rubenovitch
Dirigente de Marketing, Sophi.io
The Globe and Mail        
[email protected]
416-585-3355